OraSure Technologies Appoints Senior Vice President and General Manager of Consumer Products Business

OraSure Technologies Appoints Senior Vice President and General Manager of
Consumer Products Business

Company to Launch National Television Advertising Campaign for OraQuick(R)
In-Home HIV Test on World AIDS Day, December 1st

BETHLEHEM, Pa., Nov. 28, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today
that it has appointed Kathleen G. Weber as the Company's Senior Vice President
and General Manager, Consumer Products. Her appointment is the culmination of
an extensive national search which began this past July following the
Company's receipt of U.S. Food and Drug Administration (FDA) approval of its
OraQuick ^® In-Home HIV Test.

Ms. Weber will be responsible for the growth and success of OraSure's
OraQuick^® In-Home HIV Test and for expanding the Company's consumer products
franchise. Ms. Weber will report to Douglas A. Michels, OraSure's President
and Chief Executive Officer.

"We are very excited to have Kathy join OraSure to lead our Consumer Products
business," said Mr. Michels. "Kathy brings extensive consumer healthcare
experience to her role at OraSure. Her leadership will be instrumental in
supporting the successful U.S. launch of our OraQuick^® In-Home HIV Test and
expanding our consumer products business in both the U.S. and international

Ms. Weber has nearly 25 years of direct to consumer health care and marketing
experience. She most recently served as Senior Vice President at Pfizer
Consumer Healthcare where she directed the Global Rx-to-OTC switch team and
managed the $700 million U.S. Analgesics and Respiratory businesses including
the Advil^® brand. While at Pfizer, Ms. Weber also managed topical healthcare
businesses including the Neosporin^®, Bengay^®, Desitin^®, Purell^® and
Cortizone-10^® brands.

Prior to Pfizer, Ms. Weber served as Vice President, Marketing for Johnson &
Johnson Consumer Healthcare where she headed up the $1.3 billion oral care and
sanitary protection categories for the Listerine^®, REACH^®, Stayfree^® and
Carefree^® brands. Earlier in her career, she led critical aspects of the
largest ever Rx-to-OTC switch at Schering Plough when Claritin^® went over the

Ms. Weber received a B.S. degree in business administration from Georgetown
University and earned an MBA from New York University's Stern School of

OraQuick^® In-Home HIV Test National Television Advertising Campaign

The Company also announced today that it will launch its OraQuick^® In-Home
HIV Test television advertising campaign on December 1st, to coincide with
World AIDS Day. The campaign will air on major cable networks, a sampling of
which includes MTV, A&E, BET, E!, Bravo and Logo and also on the nation's
number one rated reality show NBC's The Voice on December 17th. The TV
advertising campaign will complement the digital advertising campaign already
in progress and comes at a time when retail distribution efforts have reached
optimal levels.

The TV advertising campaign, originally scheduled to commence in January 2013,
is not expected to impact OraSure's previously announced financial guidance
for the fourth quarter.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market – making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their

The OraSure Technologies, Inc. logo is available at

For more information on OraSure Technologies, please visit www.orasure.com.

Important Information

This press release contains certain forward-looking statements, including with
respect to expected revenues and earnings/loss per share. Forward-looking
statements are not guarantees of future performance or results. Known and
unknown factors that could cause actual performance or results to be
materially different from those expressed or implied in these statements
include, but are not limited to: ability to market and sell products, whether
through an internal, direct sales force or third parties; ability to
manufacture products in accordance with applicable specifications, performance
standards and quality requirements; ability to obtain, and timing and cost of
obtaining, necessary regulatory approvals for new products or new indications
or applications for existing products; ability to comply with applicable
regulatory requirements; changes in relationships, including disputes or
disagreements, with strategic partners or other parties and reliance on
strategic partners for the performance of critical activities under
collaborative arrangements; failure of distributors or other customers to meet
purchase forecasts or minimum purchase requirements for the Company's
products; impact of replacing distributors and success of direct sales
efforts; inventory levels at distributors and other customers; ability to
integrate and realize the full benefits of the Company's acquisition of DNA
Genotek; ability of DNA Genotek to achieve its financial and strategic
objectives; ability to identify, complete, integrate and realize the full
benefits of future acquisitions; impact of competitors, competing products and
technology changes; impact of the economic downturn, high unemployment and
poor credit conditions; reduction or deferral of public funding available to
customers; competition from new or better technology or lower cost products;
ability to develop, commercialize and market new products, including the
OraQuick® In-Home HIV Test; market acceptance of oral fluid testing or other
products; changes in market acceptance of products based on product
performance, extended shelf life or other factors; ability to fund research
and development and other products and operations; ability to obtain and
maintain new or existing product distribution channels; reliance on sole
supply sources for critical product components; availability of related
products produced by third parties or products required for use of our
products; history of losses and ability to achieve sustained profitability;
ability to utilize net operating loss carry forwards or other deferred tax
assets; volatility of our stock price; uncertainty relating to patent
protection and potential patent infringement claims; uncertainty and costs of
litigation relating to patents and other intellectual property; availability
of licenses to patents or other technology; ability to enter into
international manufacturing agreements; obstacles to international marketing
and manufacturing of products; ability to sell products internationally,
including the impact of changes in international funding sources and testing
algorithms; adverse movements in foreign currency exchange rates; loss or
impairment of sources of capital; ability to retain qualified personnel;
exposure to product liability and other types of litigation; changes in
international, federal or state laws and regulations; customer consolidations
and inventory practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil unrest;
and general political, business and economic conditions. These and other
factors are discussed more fully in the Company'sSecurities and Exchange
Commission filings, including its registration statements, Annual Report on
Form 10-K for the year ended December 31, 2011, Quarterly Reports on Form
10-Q, and other filings with the SEC. Although forward-looking statements help
to provide information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. The forward-looking
statements are made as of the date of this press release and OraSure
Technologies undertakes no duty to update these statements.

CONTACT: Media Contact:
         Jennifer Moritz
         Zer0 to 5ive for OraSure Technologies

company logo
Press spacebar to pause and continue. Press esc to stop.